A Phase I clinical trial of EUS-guided intratumoral injection of the oncolytic virus, HF10 for unresectable locally advanced pancreatic cancer

Table 3 Efficacy evaluation

Patient no.		Evaluation (RECIST ver 1.1)			Time to response (days)	Duration of response (days)	PFS (days)	OS (days)
Patient no.		Target response	Overall response	Surgical response	Time to response (days)	Duration of response (days)	PFS (days)	OS (days)
Cohort 1	HF-1-02	SD	PD				119	150
	HF-1-04	SD	PD				91	465
	HF-1-05	PR	PR	CR	48	288	335	611
Cohort 2	HF-2-01	SD	SD				663	1211
	HF-2-02	PR	PR	CR	13	444	456	1189
	HF-2-03	SD	SD				48	336
Cohort 3	HF-3-02	SD	SD				217	694
	HF-3-03	SD	SD				69	273
	HF-3-04	PR	PR		34	156	189	255

PFS progression free survival, OS overall survival, PR partial response, SD stable disease, CR complete response

ISSN: 1471-2407